Published 1 day ago • loading... • Updated 1 day ago

Johnson & Johnson Pops on Top- and Bottom-Line Beat, Boost to Full-Year Outlook

The drugmaker’s “grind it out” year is paying off, with sales jumping even as its blockbuster treatment faces more competition....

3 Articles

sherwood.news

Lean Left

Johnson & Johnson pops on top- and bottom-line beat, boost to full-year outlook

The drugmaker’s “grind it out” year is paying off, with sales jumping even as its blockbuster treatment faces more competition....

1 day ago

Read Full Article

sta.si

Sta: Johnson & Johnson Exceeds Expectations with Quarterly Profit and Revenue

American pharmaceutical giant Johnson & Johnson reported lower profit in the second quarter of this year than in the same quarter last year. It amounted to $2.77 per share, which is 1.8 percent less than last year, but still more than Wall Street analysts expected, business television channel CNBC reported.

1 day ago

Read Full Article

endpoints.news

Updated: J&J's Stelara faces continued biosimilar competition, with Q2 revenue falling 43%

Johnson & Johnson said revenue for its megablockbuster Stelara continued to decline in the face of emerging biosimilar competition. The company said Tuesday that global sales of Stelara were down 42 ...

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year